Business
Telo Genomics Launches Multiple Myeloma Advisory Board at the American Society of Hematology Annual Meeting
Toronto, Ontario--(Newsfile Corp. - February 22, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Launches Multiple Myeloma Advisory Board at the American Society of Hematology Annual MeetingToronto, Ontario--(Newsfile Corp. - February 22, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo\") is excited to announce the launch of our inaugural multiple myeloma clinical advisory board (\"MM CAB\"). The advisory group met at the American Society of Hematology (\"ASH\") meeting in New Orleans on December 13, 2022. This internationally recognized group of clinical advisors provided feedback and advice to the Telo management team in advance of the company's launch of TeloView-MM, a predictive and prognostic test for smouldering multiple myeloma (\"SMM\"). In addition to feedback from Dr. Richard Bender, Telo's MM CAB Chair, the meeting featured world-renowned clinicians in the management of MM who have contributed significantly to the advancement of MM disease management globally. Included were:Dr. Kenneth Anderson: Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics - Harvard Medical SchoolDr. Shaji Kumar: Medical Director for the Cancer Center Clinical Trials Office - Mayo ClinicDr. Elisabet Manasanch: Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine - The University of Texas MD Anderson Cancer Center\"As referenced in prior releases, Telo Genomics has reached an inflection point where clinical validation, advances in laboratory automation and optimization of the TeloView platform have coalesced to put Telo on the doorstep of commercial launch,\" said Kris Weinberg, Telo Genomics CEO. \"The CAB is of great value in helping us build and sustain momentum by advising on the current standard of care for SMM while suggesting further validation strategies, pipeline and line extensions, as well as market positioning for TeloView-MM.\"Telo's lead product is designed to identify high-risk smoldering multiple myeloma (\"SMM\") patients who are likely to benefit from earlier treatment intervention. The test also identifies the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment. These patients can be regularly monitored using TeloView-MM. The Company's second assay is designed to identify newly diagnosed Multiple Myeloma patients who are most like...